Skip to content

Cutaneous Leishmaniasis Diagnostic Study

Diagnosis of Cutaneous Leishmaniasis Using the CL-Detect Rapid Test in Ethiopia

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03837431
Enrollment
351
Registered
2019-02-12
Start date
2019-02-13
Completion date
2023-01-31
Last updated
2023-03-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cutaneous Leishmaniases

Keywords

Cutaneous, Leishmaniasis, Ethiopia, RDT

Brief summary

The performance of the CL Detect Rapid test will be tested in individuals with suspected cutaneous leishmaniasis in Ethiopia using both skin slit and dental broach samples against a combined reference of microscopy and PCR. Alternative sampling methods will also be evaluated.

Detailed description

Cutaneous Leishmaniasis is common in Ethiopia and mainly affects the poor living in rural areas. Diagnosis of CL routinely uses invasive skin slits which are examined with microscopy, requiring trained staff and an equipped lab. A new rapid diagnostic test for CL which may be used in the field has been developed and validated in several countries where other Leishmania species are present. Less invasive tape sampling has also become available. Whether this new RDT and alternative sampling methods can be used in Ethiopia is unclear. The performance of the CL detect Rapid Test against a combined reference (microscopy and PCR) and alternative sample collection methods will be tested in CL suspected individuals in North-West Ethiopia in a cross-sectional study.

Interventions

DIAGNOSTIC_TESTSkin slit

Skin slit microscopy, RDT and PCR

DIAGNOSTIC_TESTDental broach

Dental broach RDT and PCR

DIAGNOSTIC_TESTTape disc

Tape disc PCR

Sponsors

Institute of Tropical Medicine, Belgium
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
2 Years to No maximum
Healthy volunteers
No

Inclusion criteria

\- Clinical suspicion of CL

Exclusion criteria

* ≤ 2 years of age * Not willing or able to provide consent/assent * CL presentation with only lesions for which skin slit samples cannot be obtained (e.g. eyelids) * Co-morbidity with visceral leishmaniasis * On CL treatment at time of enrollment

Design outcomes

Primary

MeasureTime frameDescription
Sensitivity, specificity of CL detect Rapid Test using skin slit samplingFebruary 2019% test positive/negative compared against a combined reference of microscopy and PCR with skin slit sampling(positive if any of the two are positive)

Secondary

MeasureTime frameDescription
Sensitivity, specificity of CL detect Rapid Test with skin slit or dental broach samplingMay 2018CL detect Rapid Test with skin slit sample against CL detect Rapid Test with dental broach sample
Sensitivity, specificity of CL detect Rapid Test compared to routineFebruary 2019CL detect Rapid Test positive/negative with skin slit sample compared to microscopy with skin slit sample
Sensitivity, specificity of dental broach sample compared to skin slit sampleFebruary 2019PCR with dental broach compared to PCR with skin slit sample
Sensitivity, specificity of CL detect Rapid Test using dental broach samplingFebruary 2019CL detect Rapid Test against combined reference of microscopy and PCR using skin slit sampling
Sensitivity, specificity of routine testingFebruary 2019Microscopy with skin slit sampling compared to PCR with skin slit sampling
Species identificationFebruary 2019For selected CL lesions species identification will be done
Immunomodulatory mediators in CL lesions using non-invasive samplingFebruary 2019Tape disc samples will be used and correlation with lesion severity will be assessed
Sensitivity, specificity of tape disc samplingFebruary 2019PCR with tape disc sampling compared to PCR with skin slit sampling

Countries

Ethiopia

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 13, 2026